The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.
Identifieur interne : 000651 ( PubMed/Curation ); précédent : 000650; suivant : 000652The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.
Auteurs : M. Lagière [France] ; S. Navailles ; L. Mignon ; A. Roumegous ; M-F Chesselet ; P. De DeurwaerdèreSource :
- Experimental brain research [ 1432-1106 ] ; 2013.
English descriptors
- KwdEn :
- Administration, Oral, Animals, Basal Ganglia (drug effects), Basal Ganglia (metabolism), Corpus Striatum (drug effects), Corpus Striatum (metabolism), Disease Models, Animal, Electrophysiological Phenomena (physiology), Entopeduncular Nucleus (drug effects), Entopeduncular Nucleus (metabolism), Ethylamines (administration & dosage), Ethylamines (pharmacology), Globus Pallidus (drug effects), Globus Pallidus (metabolism), Indoles (administration & dosage), Indoles (pharmacology), Male, Neurons (drug effects), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Rats, Rats, Sprague-Dawley, Serotonin (metabolism), Serotonin 5-HT2 Receptor Agonists (administration & dosage), Serotonin 5-HT2 Receptor Agonists (pharmacology), Substantia Nigra (drug effects), Substantia Nigra (metabolism).
- MESH :
- chemical , administration & dosage : Ethylamines, Indoles, Serotonin 5-HT2 Receptor Agonists.
- drug effects : Basal Ganglia, Corpus Striatum, Entopeduncular Nucleus, Globus Pallidus, Neurons, Substantia Nigra.
- drug therapy : Parkinson Disease.
- metabolism : Basal Ganglia, Corpus Striatum, Entopeduncular Nucleus, Globus Pallidus, Parkinson Disease, Serotonin, Substantia Nigra.
- chemical , pharmacology : Ethylamines, Indoles, Serotonin 5-HT2 Receptor Agonists.
- physiology : Electrophysiological Phenomena.
- Administration, Oral, Animals, Disease Models, Animal, Male, Rats, Rats, Sprague-Dawley.
Abstract
Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.
DOI: 10.1007/s00221-013-3478-4
PubMed: 23535834
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000679
Links to Exploration step
pubmed:23535834Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.</title>
<author><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M" last="Lagière">M. Lagière</name>
<affiliation wicri:level="1"><nlm:affiliation>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifique, Université Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifique, Université Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S" last="Navailles">S. Navailles</name>
</author>
<author><name sortKey="Mignon, L" sort="Mignon, L" uniqKey="Mignon L" first="L" last="Mignon">L. Mignon</name>
</author>
<author><name sortKey="Roumegous, A" sort="Roumegous, A" uniqKey="Roumegous A" first="A" last="Roumegous">A. Roumegous</name>
</author>
<author><name sortKey="Chesselet, M F" sort="Chesselet, M F" uniqKey="Chesselet M" first="M-F" last="Chesselet">M-F Chesselet</name>
</author>
<author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23535834</idno>
<idno type="pmid">23535834</idno>
<idno type="doi">10.1007/s00221-013-3478-4</idno>
<idno type="wicri:Area/PubMed/Corpus">000679</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000679</idno>
<idno type="wicri:Area/PubMed/Curation">000651</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000651</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.</title>
<author><name sortKey="Lagiere, M" sort="Lagiere, M" uniqKey="Lagiere M" first="M" last="Lagière">M. Lagière</name>
<affiliation wicri:level="1"><nlm:affiliation>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifique, Université Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifique, Université Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Navailles, S" sort="Navailles, S" uniqKey="Navailles S" first="S" last="Navailles">S. Navailles</name>
</author>
<author><name sortKey="Mignon, L" sort="Mignon, L" uniqKey="Mignon L" first="L" last="Mignon">L. Mignon</name>
</author>
<author><name sortKey="Roumegous, A" sort="Roumegous, A" uniqKey="Roumegous A" first="A" last="Roumegous">A. Roumegous</name>
</author>
<author><name sortKey="Chesselet, M F" sort="Chesselet, M F" uniqKey="Chesselet M" first="M-F" last="Chesselet">M-F Chesselet</name>
</author>
<author><name sortKey="De Deurwaerdere, P" sort="De Deurwaerdere, P" uniqKey="De Deurwaerdere P" first="P" last="De Deurwaerdère">P. De Deurwaerdère</name>
</author>
</analytic>
<series><title level="j">Experimental brain research</title>
<idno type="eISSN">1432-1106</idno>
<imprint><date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration, Oral</term>
<term>Animals</term>
<term>Basal Ganglia (drug effects)</term>
<term>Basal Ganglia (metabolism)</term>
<term>Corpus Striatum (drug effects)</term>
<term>Corpus Striatum (metabolism)</term>
<term>Disease Models, Animal</term>
<term>Electrophysiological Phenomena (physiology)</term>
<term>Entopeduncular Nucleus (drug effects)</term>
<term>Entopeduncular Nucleus (metabolism)</term>
<term>Ethylamines (administration & dosage)</term>
<term>Ethylamines (pharmacology)</term>
<term>Globus Pallidus (drug effects)</term>
<term>Globus Pallidus (metabolism)</term>
<term>Indoles (administration & dosage)</term>
<term>Indoles (pharmacology)</term>
<term>Male</term>
<term>Neurons (drug effects)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Serotonin (metabolism)</term>
<term>Serotonin 5-HT2 Receptor Agonists (administration & dosage)</term>
<term>Serotonin 5-HT2 Receptor Agonists (pharmacology)</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Ethylamines</term>
<term>Indoles</term>
<term>Serotonin 5-HT2 Receptor Agonists</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Basal Ganglia</term>
<term>Corpus Striatum</term>
<term>Entopeduncular Nucleus</term>
<term>Globus Pallidus</term>
<term>Neurons</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Basal Ganglia</term>
<term>Corpus Striatum</term>
<term>Entopeduncular Nucleus</term>
<term>Globus Pallidus</term>
<term>Parkinson Disease</term>
<term>Serotonin</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Ethylamines</term>
<term>Indoles</term>
<term>Serotonin 5-HT2 Receptor Agonists</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Electrophysiological Phenomena</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Administration, Oral</term>
<term>Animals</term>
<term>Disease Models, Animal</term>
<term>Male</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23535834</PMID>
<DateCreated><Year>2013</Year>
<Month>10</Month>
<Day>01</Day>
</DateCreated>
<DateCompleted><Year>2014</Year>
<Month>05</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>10</Month>
<Day>01</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1106</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>230</Volume>
<Issue>4</Issue>
<PubDate><Year>2013</Year>
<Month>Oct</Month>
</PubDate>
</JournalIssue>
<Title>Experimental brain research</Title>
<ISOAbbreviation>Exp Brain Res</ISOAbbreviation>
</Journal>
<ArticleTitle>The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates.</ArticleTitle>
<Pagination><MedlinePgn>513-24</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s00221-013-3478-4</ELocationID>
<Abstract><AbstractText>Lesions of nigrostriatal dopaminergic neurons as seen in Parkinson's disease (PD) increase orofacial responses to serotonergic (5-HT) agonists in rodents. Although this response to 5-HT agonists has been related to aberrant signalling in the basal ganglia, a group a subcortical structures involved in the control of motor behaviours, it deserves additional studies with respect to the specific loci involved. Using measurements of orofacial activity, as well as single-cell recordings in vivo, we have studied the role of the entopeduncular nucleus (EPN; equivalent to the internal globus pallidus of primates), an output structure of basal ganglia, in the hypersensitized responses to a 5-HT agonist in sham- or unilaterally dopamine-depleted rats. Intra-EPN injections of Ro 60-0175 (0.3 and 1 μg/100 nl) promoted robust oral movements in 6-OHDA rats without affecting oral activity in sham-depleted rats. Peripheral administration of Ro 60-0175 (3 mg/kg ip) decreased EPN neuronal firing rate in 6-OHDA rats compared to sham-depleted rats. Such an effect was also observed when the agonist (0.2 μg/20 nl) was locally applied onto EPN neurons. These data demonstrate the contribution of EPN to hypersensitized responses to 5-HT agonists in a rat model of PD.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lagière</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Unité Mixte de Recherche 5293, Centre National de la Recherche Scientifique, Université Bordeaux, 146, rue Léo Saignat, 33076, Bordeaux Cedex, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Navailles</LastName>
<ForeName>S</ForeName>
<Initials>S</Initials>
</Author>
<Author ValidYN="Y"><LastName>Mignon</LastName>
<ForeName>L</ForeName>
<Initials>L</Initials>
</Author>
<Author ValidYN="Y"><LastName>Roumegous</LastName>
<ForeName>A</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chesselet</LastName>
<ForeName>M-F</ForeName>
<Initials>MF</Initials>
</Author>
<Author ValidYN="Y"><LastName>De Deurwaerdère</LastName>
<ForeName>P</ForeName>
<Initials>P</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>P50-NS 38367</GrantID>
<Acronym>NS</Acronym>
<Agency>NINDS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant><GrantID>R37-MH44894</GrantID>
<Acronym>MH</Acronym>
<Agency>NIMH NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2013</Year>
<Month>03</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Germany</Country>
<MedlineTA>Exp Brain Res</MedlineTA>
<NlmUniqueID>0043312</NlmUniqueID>
<ISSNLinking>0014-4819</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D005021">Ethylamines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D007211">Indoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C103848">Ro 60-0175</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D058826">Serotonin 5-HT2 Receptor Agonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>333DO1RDJY</RegistryNumber>
<NameOfSubstance UI="D012701">Serotonin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001479" MajorTopicYN="N">Basal Ganglia</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003342" MajorTopicYN="N">Corpus Striatum</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D055724" MajorTopicYN="N">Electrophysiological Phenomena</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020392" MajorTopicYN="N">Entopeduncular Nucleus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005021" MajorTopicYN="N">Ethylamines</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005917" MajorTopicYN="N">Globus Pallidus</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007211" MajorTopicYN="N">Indoles</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017207" MajorTopicYN="N">Rats, Sprague-Dawley</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058826" MajorTopicYN="N">Serotonin 5-HT2 Receptor Agonists</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013378" MajorTopicYN="N">Substantia Nigra</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year>
<Month>01</Month>
<Day>16</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2013</Year>
<Month>03</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2013</Year>
<Month>3</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2013</Year>
<Month>3</Month>
<Day>29</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2014</Year>
<Month>5</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">23535834</ArticleId>
<ArticleId IdType="doi">10.1007/s00221-013-3478-4</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000651 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000651 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonFranceV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:23535834 |texte= The enhanced oral response to the 5-HT2 agonist Ro 60-0175 in parkinsonian rats involves the entopeduncular nucleus: electrophysiological correlates. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:23535834" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a ParkinsonFranceV1
![]() | This area was generated with Dilib version V0.6.29. | ![]() |